Found vs TMates: Affordable biology-first care vs $199 flat plan
Quick comparison: Found vs TMates and early verdict
Found and TMates both deliver telehealth weight loss care using compounded or branded GLP-1 options, but they target different priorities. Early verdict: choose Found if you want a biology-first, insurance-friendly, lower-starting-cost program; choose TMates if you want a flat $199/month semaglutide plan with 24/7 U.S. physician availability.
Explore Found plans starting at $39
Top differences at a glance
This comparison focuses on five supported differences: starting price and pricing model, insurance handling and coverage, medication options and formulation, clinician access and oversight, and regulatory notes about compounded medications.
Starting price and pricing model
Found advertises programs you can get started for as low as $39 and highlights affordable monthly plans. TMates advertises a flat $199/month price that stays the same at every dose, with plan tiers shown for multi month options. That makes Found the lower entry cost option, while TMates uses a single flat monthly fee that avoids step up fees as dosage escalates.
See TMates flat $199/month plan
Insurance handling and payments
Found states that most insurance is now accepted, that it handles insurance paperwork, and that Medicare programs and insurance coverage vary. Found says medication coverage and copays vary based on eligibility and insurance approval and that advertised pricing for branded GLP-1s may require a 12 month commitment. TMates is described in source FAQ as operating on a direct-pay model and does not bill insurance, offering transparent flat pricing without prior authorization steps. These are materially different approaches to insurance and billing.
Medication types and availability
Found lists tirzepatide, compounded semaglutide, and mentions branded options like Wegovy or Zepbound where available through insurance, while noting that compounded GLP-1s are not FDA-approved and are not available in all states. TMates focuses on compounded semaglutide formulated in U.S. facilities; public detail on tirzepatide availability is limited. Both sources emphasize compounded semaglutide as an option but Found explicitly references both compounded and branded pathways depending on insurance and eligibility.
Clinician access and program oversight
Found emphasizes a biology-first, personalized medically supervised program that evaluates hormones, blood sugar regulation, sleep, and behavioral factors to build individualized plans. TMates emphasizes 24/7 access to U.S.-based doctors, licensed coverage in all 50 states, and virtual check-in appointments for ongoing oversight. In short, Found highlights personalized metabolic evaluation and holistic care while TMates highlights round the clock physician availability and consistent dosing oversight.
Regulatory and safety notes
Both sources include the regulatory caveat that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality. Found also repeats that compounded GLP-1s are not FDA-approved or evaluated for safety or efficacy and may not be available in all states. TMates notes that its compounded semaglutide uses the same active ingredient as Ozempic and Wegovy but remains a compounded product.
| Criteria | Found | TMates |
|---|---|---|
| Starting price | Get started for as low as $39 | $199/month flat |
| Pricing model | Affordable monthly plans; varied plan tiers and offers | Flat $199/month, same price at every dose; multi month tiers listed |
| Insurance | Most insurance now accepted; Found handles insurance paperwork | Operates on a direct-pay model and does not bill insurance (per source FAQ) |
| Medication options | Compounded semaglutide, tirzepatide, and branded options via insurance when available | Clinically dosed compounded semaglutide formulated in U.S. facilities; limited public detail on tirzepatide |
| Clinician access | Personalized medically supervised, biology-first evaluations | 24/7 U.S.-based doctor access and virtual check-ins |
| Regulatory note | Compounded medications are not FDA-approved and not reviewed by FDA | Compounded medications are not FDA-approved and not reviewed by FDA |
Making the choice: which to pick
Found vs TMates comes down to whether you prioritize lower entry cost and insurance integration or consistent flat pricing and 24/7 physician availability. Found is positioned as a biology-first, holistic program that accepts most insurance and handles paperwork, offers tirzepatide and branded options where eligible, and advertises starting plans as low as $39. TMates is positioned as a straightforward, flat $199/month compounded semaglutide program with 24/7 U.S. doctor access and U.S.-formulated medication.
Compare Found membership options
Choose Found if…
- You want a biology-first, personalized medically supervised program that evaluates hormones, sleep, and metabolism.
- You want the potential to use insurance and have a lower advertised starting price, with Found handling insurance paperwork.
- You value broader medication pathways including tirzepatide and branded GLP-1s when available via insurance.
Choose TMates if…
- You prefer a predictable flat $199/month price that does not increase with higher doses and includes free shipping.
- You want 24/7 access to U.S.-based doctors, virtual check-ins, and compounded semaglutide formulated in U.S. facilities.
Found vs TMates: both use compounded options and note that compounded medications are not FDA-approved. Decide based on whether pricing structure, insurance handling, or continuous physician access matters more to your care plan.